NASDAQ · ACRS
Aclaris Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for ACRS: Nov 5, 2026
Aclaris Therapeutics, Inc. Common Stock is estimated to report earnings on 11/05/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 5 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.16. The reported EPS for the same quarter last year was $-0.12.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.16 | $-0.15 | $-0.17 | 5 |
| Dec 2026 | $-0.16 | $-0.14 | $-0.17 | 5 |
| Mar 2027 | $-0.15 | $-0.13 | $-0.18 | 4 |
| Jun 2027 | $-0.15 | $-0.12 | $-0.19 | 4 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Fintel · MarketBeat · RTTNews · Zacks- Fintel · Oct 27, 11:48 PM EDTAclaris Therapeutics, Inc. Enters Underwriting Agreement for Offering of 7,785,714 Shares of Common Stock and 6,500,000 Pre-Funded WarrantsOn October 27, 2026, Aclaris Therapeutics, Inc. entered into an underwriting agreement to issue and sell 7,785,714 shares of common stock of the Company, par value $0.00001 per share, and pre-funded warrants to purchase 6,500,000 shares of Common Stock. The offering price is $3.5
- MarketBeat · Oct 27, 6:04 PM EDTAclaris Therapeutics ATI-052 Posts Early Eczema, Asthma Signals in Phase 1b3 Penny Stocks Under $5 Backed by Real Revenue GrowthAclaris Therapeutics (NASDAQ:ACRS) reported Phase 1b proof-of-concept results for ATI-052, its bispecific antibody designed to inhibit thymic stromal lymphopoietin (TSLP) and IL-4 receptor alpha, in small studies of atopic derm
- Fintel · Oct 27, 7:52 AM EDTAclaris Therapeutics, Inc. Announces Phase 1b Results for ATI-052 and Estimates $204.6 million in CashAclaris Therapeutics, Inc. announced primary analysis results from its Phase 1b proof-of-concept trials of ATI-052, an anti-TSLP/IL-4Rα bispecific antibody, in patients with severe atopic dermatitis and mild-to-moderate asthma. In the atopic dermatitis trial, which evaluate
- RTTNews · Oct 27, 7:29 AM EDTAclaris Reports Positive Phase 1b Results For ATI-052 In Atopic Dermatitis And Asthma; Stock Down(RTTNews) – Aclaris Therapeutics Inc. (ACRS) reported positive Phase 1b proof-of-concept results for ATI-052, an investigational antibody designed to target multiple pathways involved in inflammation, with improvements in skin symptoms and lung function observed in separate trial
- Zacks · Oct 21, 8:40 AM EDTAre Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?Here is how Aclaris Therapeutics (ACRS) and Glaukos (GKOS) have performed compared to their sector so far this year.
- Zacks · Sep 15, 8:47 AM EDTAclaris (ACRS) Soars 6.0%: Is Further Upside Left in the Stock?Aclaris (ACRS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- Fintel · Sep 2, 5:48 PM EDTCanaccord Genuity Initiates Coverage of Aclaris Therapeutics (ACRS) with Buy RecommendationFintel reports that on September 1, 2026, Canaccord Genuity initiated coverage of Aclaris Therapeutics (NASDAQGS:ACRS) with a Buy recommendation. Analyst Price Forecast Suggests 68.66% Upside
- Zacks · Aug 10, 9:55 AM EDTWall Street Analysts Believe Aclaris (ACRS) Could Rally 69.2%: Here's is How to TradeThe consensus price target hints at a 69.2% upside potential for Aclaris (ACRS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- RTTNews · Aug 7, 1:20 AM EDTAclaris Q2 Net Loss Expands; Secures FDA's Fast Track Designation For Modzatinib In Lichen Planus(RTTNews) – Aclaris Therapeutics, Inc. (ACRS), a clinical-stage biopharmaceutical company, announced financial results for the second quarter reflecting a wider net loss. In addition, the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its lead in
- Zacks · Aug 6, 8:20 AM EDTAclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue EstimatesAclaris (ACRS) delivered earnings and revenue surprises of +6.25% and +17.19%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- RTTNews · Aug 6, 4:54 AM EDTBiotech Stocks At 52-Week Highs – BVS, TVTX, ODTX, CRL Climb With Q2 Results, ACRS(RTTNews) – The following biotech stocks reached a 52-week high on August 5, 2026, primarily driven by positive quarterly reports.
- RTTNews · Jul 21, 3:41 AM EDTBiotech Stocks At 52-Week Highs – XNCR, COAG, MNPR, SOPH, ACRS(RTTNews) – The following biotech stocks reached a 52-week high on July 20, 2026, driven by key catalysts such as upcoming clinical trial launches and the prospective release of data from these studies.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Aclaris Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.